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YAP and TAZ are transcription coactivators and effectors of the Hippo pathway, which play a key role in organ size
control. Through interaction with transcription factors such as TEADs, they activate gene transcription and thus
promote cell proliferation, inhibit apoptosis, and regulate cell differentiation. Dysregulation of YAP/TAZ was found
to correlate with human cancers. The oncogenic roles of these proteins were also demonstrated in animal models.
The growth promoting activity of YAP/TAZ is limited by the Hippo tumor suppressor pathway through
phosphorylation-induced cytoplasmic retention and destabilization. Recently, it was found that YAP and TAZ
mediate responses to several extracellular signals including mechanical stress, GPCR signaling, and the Wnt
signaling pathway. All these growth-regulating signals play important roles in normal development and cancer. In
this review, we would like to discuss the function of YAP and TAZ as effectors of these physiological signals.
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The precise control of cell number during development
and regeneration maintains organ size homeostasis of
multicellular organisms. In recent years, the Hippo sig-
naling pathway is emerging as a key regulator of organ
size [1,2]. The Hippo pathway was first identified in
Drosophila by genetic mosaic screens for growth inhibi-
tory genes [3-12]. Then the pathway and its function
in organ size control were found to be conserved in
mammals [13,14]. Yes-associated protein (YAP) and its
homolog transcriptional co-activator with PDZ-binding
motif (TAZ, also called WWTR1) are key downstream
effectors of the Hippo pathway being phosphorylated
and inhibited by the Hippo pathway kinases Last1/2
[13,15]. YAP and TAZ activate gene transcription through
interaction with transcription factors such as the four
TEAD family proteins [16,17]. YAP/TAZ-induced gene
expression results in cell proliferation, evasion of apop-
tosis, and also amplification of progenitor/stem cells thus
promotion of organ size. Consistently, recent studies on
animal models also demonstrate a role of the Hippo path-
way and YAP in tissue regeneration [18,19]. Furthermore,
there are ever-accumulating reports on the correlation of* Correspondence: binzhao@zju.edu.cn
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reproduction in any medium, provided the orabnormal YAP/TAZ activation with human cancers
[20-23]. However, upstream signals regulating the Hippo
pathway and YAP/TAZ were obscure until the publication
of several recent studies [24-28]. In this review we discuss
the roles of YAP/TAZ as mediators of responses to mech-
anical stress, GPCR signaling and the Wnt signaling.Biochemical and biological functions of YAP/TAZ
YAP was first cloned as a protein bound to non-receptor
tyrosine kinase YES1 [29]. YAP mRNA is ubiquitously
expressed in a wide range of tissues, except peripheral
blood leukocytes [30]. There are two major splicing vari-
ants with one (YAP1) or two (YAP2) WW domains. The
function of YAP remained enigmatic until it was shown
to be a transcription co-activator [31]. A reporter assay
demonstrated that the C-terminal region of YAP has
strong transcriptional activation activity. However, it
does not directly bind to DNA. Instead, it is brought to
gene promoters through the interaction with transcrip-
tion factors. First identified by affinity purification [32],
TEAD family transcription factors are major partners of
YAP in regulation of cell proliferation and organ size
[17]. The importance of TEADs in the function of YAP
was nicely demonstrated by a mouse model with knock-
in of a mutant YAP deficient in interaction with TEAD.
Remarkably, the knock-in mice showed skin phenotypesal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Furthermore, a heterozygous YAP-binding-deficient muta-
tion of TEAD1 leads to a human genetic disease Sveinsson’s
chorioretinal atrophy [17,34,35], which further illustrates
the physiological importance of TEAD in YAP function.
Through the centrally localized WW domains, YAP also
interacts with other transcription factors such as RUNX1/2
and Smad1 [31,36], which may also contribute to YAP-
induced gene expression and organ size control. The me-
chanism by which YAP activates transcription is still
elusive. However, the Drosophila homolog of YAP, Yki, was
shown to interact with GAGA factor (GAF), the Brahma
complex, and the Mediator complex in cell nuclei to acti-
vate gene expression [37]. Interestingly, another report
demonstrated that Scalloped (Sd), the Drosophila homolog
of TEADs, function as a default transcription repressor by
binding to Tgi [38]. When activated, Yki competes with Tgi
for Sd binding and thus switches Sd from OFF to an ON
state. Importantly, the function of Tgi is conserved in its
mammalian homolog Vestigial-like 4 (Vgl4) [38].
YAP has an evolutionarily conserved function in organ
size control. For instance, liver-specific overexpression of
YAP in transgenic mice results in enlarged liver, which is
reversible upon cessation of YAP overexpression [14,39].
However, sustained YAP overexpression eventually leads
to the development of liver tumors [14]. Examination of
clinical samples identified genomic amplification as well
as elevated expression and nuclear localization of YAP in
human cancers [13,14,20,21,40]. Further experiments on
cultured cells supported the function of YAP in inducing
cell transformation, loss of cell-contact-inhibition, and
epithelial-mesenchymal transition (EMT) [13,41]. Thus
current findings indicate an oncogenic role of YAP. YAP
activation also promotes the expansion of tissue-specific
progenitor cells such as in skin, chicken neural tube, and
more controversially in intestine, which would be dis-
cussed below [39,42-44]. Furthermore, YAP promotes self-
renewal of mouse ES cells and represses differentiation
[45]. Taken together, YAP has important functions in
organ size control, tumorigenesis and tissue regeneration.
TAZ is a YAP paralog initially identified as a 14-3-3
binding protein [46]. In human and mouse, TAZ mRNA
is expressed in all tissues except thymus and peripheral
blood leukocytes, with the highest expression in kidney
[46]. TAZ has approximately 50% sequence identity and
very similar topology with YAP. Clued by the trans-
cription coactivator function of YAP, TAZ was also con-
firmed to have similar activity highly dependent on
TEAD family transcription factors [16,46]. However,
some target transcription factors are unique to TAZ,
such as Smad2/3 and Pax3, which may contribute to the
differential functions of TAZ to YAP [47,48]. TAZ also
promotes cell proliferation, induces EMT, increases cell
migration and invasion in vitro [15,22], and is shown tobe overexpressed in approximately 20% of breast cancer
samples [22]. Interestingly, a recent study identified TAZ
as a key factor sustaining self-renewal of breast cancer
stem cells [23]. Despite the functional similarity of YAP
and TAZ, they still possess some clearly distinct charac-
ters. For instance, YAP and TAZ knockout mice show
different phenotypes: YAP knockout animals are embry-
onic lethal and show shortened body axis and defects in
yolk sac vasculogenesis [49]. In contrast, TAZ knockout
mice are viable and are characterized by renal cysts
which lead to end stage kidney disease [50,51]. In
addition, in many cases, the phenotype of YAP or TAZ
knockdown were not compensated by the presence of
the other [17,22,47,52]. Such differences may be ex-
plained by spatial and temporal regulation of YAP and
TAZ activity or different downstream targets, which re-
quire further study.
Mechanisms regulating YAP/TAZ activity
YAP and TAZ regulate gene expression. However, the
regulation on transcription of themselves is largely un-
known. Recently it was reported that an Ets family tran-
scription factor GABP directly promotes YAP transcription
under inhibition by oxidative stress [53]. However, most of
the known mechanisms regulating YAP/TAZ activity are
on post-translational level. The physiological significance
of YAP/TAZ was first revealed after the identification of
DrosophilaYki as a key effector of the Hippo pathway [54].
Detailed biochemical analysis indicated that YAP is directly
phosphorylated by Lats1/2 on five consensus HXRXXS
motifs [13-15,55,56]. Phosphorylation of S127 in YAP pro-
motes 14-3-3 binding, resulting in cytoplasmic sequestra-
tion and therefore inactivation of YAP [13-15,55,56].
Phosphorylation on YAP S381 primes subsequent phos-
phorylation by another kinase, possibly casein kinase 1
(CK1δ/ε), thereby activates a phosphodegron degradation
motif. Subsequently, the activated phosphodegron recruits
the E3 ubiquitin ligase SCFβ-TRCP, leading to poly-
ubiquitination and degradation of YAP [57]. The im-
portance of YAP as a downstream effector of the Hippo
pathway was elegantly demonstrated in vivo by the rever-
sal of Hippo pathway deficiency-induced oncogenic phe-
notypes by loss of one allele of YAP [58,59]. TAZ has four
conserved Lats1/2 target motifs and is regulated by the
Hippo pathway in a similar manner [15,60].
Besides the canonical Hippo pathway, YAP/TAZ are also
regulated by physical interactions with other proteins, es-
pecially cell junctional proteins. Through the WW do-
mains, YAP could interact with angiomotin (AMOT)
family proteins, which results in YAP localization to tight
junction and YAP inhibition through phosphorylation-
dependent and -independent mechanisms [61-63]. YAP
and TAZ also interact with another tight junction protein
ZO-2, which was reported to increase nuclear localization
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[64,65]. Interestingly, a major adherens junction protein
alpha-catenin, can also bind to and inhibit YAP by mediat-
ing its cell-cell junction and cytoplasmic localizations
[33,44]. Another adherens junction protein PTPN14 has
also been reported by several groups to be a negative regu-
lator of YAP through the interaction with YAP WW do-
mains [66-69]. In consistence with these finding on YAP/
TAZ regulation by junctional proteins, YAP/TAZ were
found to be regulated by cell-cell contact. In tissue culture,
high cell density induces YAP phosphorylation and cyto-
plasmic translocation [13] and disruption of cell-cell junc-
tions results in the nuclear localization of YAP/TAZ [70].
In mouse blastocysts, YAP is nuclear in outer layer cells,
and cytoplasmic in the inner blastocyst layer cells [71].
Taken together, it is clear that YAP/TAZ transcription
coactivators might mediate upstream signals through both
the Hippo pathway and their interactions with other
proteins.
YAP/TAZ mediate cellular responses to mechanical stress
Biomechanics is increasingly recognized as an important
regulator of cell physiology and a key player in develop-
ment and pathological abnormalities. For instance, many
cancers such as breast cancer have elevated tissue stiffness
due to altered ECM composition. Remarkably, softening
of the tumor microenvironment slows tumor growth and
progression [72]. It is also known that matrix stiffness is a
determinant factor for lineage commitment of mesenchy-
mal stem cells (MSCs). MSCs differentiate into adipocytes
on soft matrix whereas osteoblasts on stiff matrix [73].
However, little was known about the molecular mecha-
nisms transducing these conditions into the nucleus and
resulting in physiological response. It was known that
TAZ could promote osteogenesis and repress adipogenesis
of MSCs possibly through activation of RUNX2-
dependent gene transcription and inhibition of PPARγ-
dependent gene expression [52]. This raises an interesting
possibility of YAP/TAZ in mediating MSC differentiation
in response to mechanical stress. This speculation was re-
cently proved to be true [25]. When cells were grown on
soft matrix or on micropatterned small islands, cells
adopted a round shape and YAP/TAZ were mostly cyto-
plasmic. However, when cells were grown on stiff mate-
rials or large adhesive islands, they became nuclear and
thus active. More importantly, the activity of YAP and
TAZ determines the lineage commitment of MSCs in re-
sponse to matrix stiffness. Cell adhesion and suspension
are two conditions affect cell geometry in an analogous
but more potent way than different matrix stiffness. It was
found that YAP/TAZ subcellular localization is regulated
by cell adhesion/suspension in a way similar to matrix
stiffness [74]. Thus, YAP and TAZ are key nuclear effec-
tors of mechanical stress.Contraction of the actomyosin cytoskeleton plays a
central role in generation and transducing mechanical
forces in cells. Consistently, the regulation of YAP/TAZ
localization by mechanical stress depends on F-actin and
Rho family GTPases [25,74,75]. Disruption of F-actin or
inhibition of Rho by specific inhibitors inactivates YAP.
On the contrary, induced actin polymerization by over-
expression of F-actin nucleator diaphanous correlates with
activation of YAP/TAZ [76]. Regulation of the Drosophila
Yki by F-actin has also been demonstrated in vivo [76].
Disruption of F-actin in vivo through several different gen-
etic manipulations results in Yki activation and over-
growth of Drosophila tissue. Importantly, Yki was found
to be required for the overgrowth.
The mechanism of YAP/TAZ regulation by cytoskeleton
and mechanical stress is not completely understood. It was
reported that knockdown of Lats1/2 is insufficient to res-
cue YAP/TAZ activity in cells cultured on soft matrix [25].
Nevertheless, in another report comparing cell attachment
on stiff matrix or complete detachment, the Hippo path-
way kinases Lats1/2 was found to be activated by cell de-
tachment, also in a cytoskeleton-dependent manner [74].
And knockdown of Lats1/2 partially prevents mechanical
stress-induced YAP phosphorylation and activation [74,75].
Thus it is possible that both Lats1/2-dependent and -
independent mechanisms are involved in the YAP/TAZ
regulation by mechanical stress (Figure 1). However, the
factors and molecular mechanisms behind each possibility
are unclear and await further characterization.
The biological relevance of YAP/TAZ-mediated response
to mechanical stress has recently been demonstrated in
breast cancer. Breast tumor is featured by its higher stiff-
ness compared with normal mammary tissue, which is due
to excessive deposition of collagen by stromal cells. Inter-
estingly, it was found that YAP is activated in cancer-
associated fibroblasts (CAFs), and its function is required
for matrix stiffing [24]. Matrix stiffing further enhances
YAP activity and thus forms a positive feedback loop creat-
ing a cancerous microenvironment. It was proposed that
YAP conditioned the tumor microenvironment by stiffing
the matrix to promote cancer cell invasion, although the
role of YAP-induced secreted factors in this process was
not formally excluded. Such activity in CAFs is observed
only for YAP but not for TAZ. Nevertheless, only TAZ but
not YAP was found to be associated with CSC maintenance
and tumor progression in breast cancer [23]. Whether TAZ
in epithelial cancer cells is activated by YAP-induced matrix
stiffing awaits further confirmation. However, there seems
to be an interesting cell-type specificity and job division be-
tween YAP and TAZ in the promotion of breast cancer.
YAP/TAZ are effectors of GPCR signaling
Soluble molecules such as growth factors, morphogens,
cytokines, and hormones serve as key factors initiating
Figure 1 YAP/TAZ are effectors of mechanical stress, GPCR signaling, and the Wnt signaling pathway. Mechanisms of YAP and TAZ
regulation by mechanical stress, GPCR signaling, and the Wnt pathway as well as YAP/TAZ as modulators of the Wnt pathway are shown.
Arrowed or blunted ends indicate activation or inhibition, respectively. Dashed lines indicate unknown mechanisms.
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and activation of their cognate receptors. In fact, most
known signaling pathways involved in growth control in
development and cancer are triggered by such extracel-
lular cues. Despite the discovery of mechanical stress as
a special upstream signal for YAP/TAZ, a soluble mol-
ecule as stimulant of the Hippo pathway was elusive. It
was even unclear whether such a molecule exists. Never-
theless, two recent reports identified lysophosphatidic
acid (LPA) and sphingosine-1-phosphophate (S1P), two
related phospholipids in serum as potent activator of
YAP/TAZ [26,27] (Figure 1). Following the initial obser-
vation of serum as a strong stimulant of YAP dephos-
phorylation and nuclear localization, both groups
identified LPA and S1P as the active ingredients through
a series of elegant biochemical analysis. Further experi-
ments demonstrated that LPA and S1P activate YAP/
TAZ by binding to their respective G-protein-coupled
receptors (GPCRs) on cell surface and activation of the
downstream heterotrimeric G proteins. Rho GTPase and
remodeling of F-actin are known effectors of GPCR sig-
naling and are also required for YAP/TAZ regulation byLPA and S1P. Thus the regulation of YAP/TAZ by
mechanical stress and soluble factors converge on actin
cytoskeleton remodeling. Activation of LPA and S1P re-
ceptors leads to inhibition of Lats1/2 kinase activity and
knockdown of Lats1/2 partially blocks YAP phosphoryl-
ation induced by serum deprivation [26,27]. Thus Lats1/
2 is at least partly responsible for YAP/TAZ regulation
by LPA and S1P, although current evidence does not ex-
clude the possibility of other mechanisms being involved
in the process. However, Mst1/2 kinase activity is not
regulated by these signals and ablation of Mst1/2 does
not impair YAP/TAZ response to GPCR signaling
[26,27]. This suggests that other molecules might be in-
volved in regulation of the Hippo pathway kinases
Lats1/2 in response to GPCR signaling.
It was later reported that thrombin, which activates
protease-activated receptors, another GPCR, also stimu-
lates YAP and TAZ activity [77]. In fact, it was found
that YAP/TAZ is robustly regulated by many GPCRs
and their cognate ligands [27]. In addition, YAP/TAZ ac-
tivity could be either activated or inhibited depending
on the G proteins coupled to the receptors. For example,
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activity, whereas activation of Gαs represses YAP/TAZ
activity [27]. Therefore, YAP/TAZ seems to be a com-
mon target of GPCR signaling. It would then be interest-
ing to determine whether these regulations on YAP/TAZ
are all executed through a similar mechanism. And if
not, what would be the individual mechanisms and for
what kind of logic do these different signals converge on
the regulation of YAP/TAZ.
GPCRs are the largest family of cell surface receptors
mediating responses to a wide range of physiological sig-
nals and importantly, medicines [78]. Abnormal GPCR
signaling is also involved in cancer development in many
ways. Elevated expression of GCPRs such as PAR1 was
found in high-grade breast cancers [79]. Furthermore,
activating mutations of GPCRs have been found in sev-
eral types of cancers such as melanomas and thyroid
carcinomas [80,81]. In addition, activating mutations of
Gα proteins have also been found in cancers, which is
best exemplified by the remarkable Gαq/11 activating
mutation rate of more than 80% in uveal melanomas
[82,83]. It was reported that transgenic expression of
LPA receptor 2 in mouse mammary glands induces acti-
vation of YAP/TAZ and massive overgrowth [27,84].
Thus, activation of YAP/TAZ might be involved in can-
cer induced by aberrant GPCR signaling. Such a possi-
bility would need to be validated by experiments.
Besides the pathological role of the GPCR-YAP/TAZ
axis, it is also important to determine the role of this
mechanism in organ size control in development and re-
generation. Providing the large pool of circulating GPCR
ligands including LPA and S1P, it would be important to
identify the key player in organ size control in vivo.
YAP/TAZ as effectors and modulators of Wnt signaling
Wnt is an important morphogen in development. In the
canonical Wnt signaling pathway stimulation of Wnt
receptors on cell surface results in disassembly of the
β-catenin destruction complex. As a result, β-catenin accu-
mulates in cell nuclei to stimulate expression of Wnt target
genes [85]. In this way, β-catenin is a widely accepted ef-
fector of Wnt signaling pathway. Interestingly, a recent re-
port discovered an unexpected role of TAZ as an effector
of the Wnt pathway [28]. It was found that Wnt stimula-
tion leads to stabilization of β-catenin as well as TAZ, but
not YAP. TAZ physically interact with β-catenin and
knockdown of β-catenin increases TAZ protein level and
activity. It was proposed that β-catenin directs TAZ for
co-degradation through SCFβ-TRCP mediated ubiquitination
(Figure 1). Previously studies demonstrated that TAZ sta-
bility is regulated by phosphorylation of a C-terminal
phospho-degron by the Hippo pathway and phosphoryl-
ation of an N-terminal degron by GSK3 [60,86]. Relation-
ship between the three mechanisms has not beenestablished yet. Noteworthy, it was also reported that Wnt/
β-catenin promoted YAP protein level by activating YAP
transcription [87]. Strikingly, gene expression profiling of
mammary epithelial cells with knockdown of β-catenin or
TAZ revealed that 74% of β-catenin target genes are also
dependent on TAZ [28]. Such observations would suggest
TAZ as a fundamental effector of the Wnt signaling path-
way. However, the physiological or pathological relevance
of this hypothesis is yet to be validated. Obviously, activa-
tion or inhibition of the Wnt pathway and the Hippo
pathway results in very different phenotypes in animals
suggesting differential roles in development. Furthermore,
it was unclear whether TAZ is activated and plays a func-
tional role in colon cancers, where abnormal activation of
β-catenin plays a key role in tumorigenesis. In fact, another
report published back-to-back with the above study identi-
fied YAP, but not TAZ as an essential survival factor for
β-catenin-driven cancer cell lines [88]. In this study, 85
cancer cell lines were divided into β-catenin active and in-
active groups based on TCF4 reporter activity. Further
RNAi screen identified YAP as an essential gene for sur-
vival and anchorage-independent growth of β-catenin
active cancer cell lines. However, suppression of TAZ ex-
pression did not affect the proliferation of these cell lines.
Surprisingly, further experiments indicated that YAP sup-
ported the survival of β-catenin active cancer cells by part-
ner with transcription factor TBX5 under the help of
tyrosine kinase YES1. This transcriptional complex stimu-
lates expression of genes such as BCL2L1 and BIRC5 to
support cancer cell survival. However, the involvement of
major YAP/TAZ target transcription factors, the TEAD
family proteins, has not been excluded by experiments. Al-
though TCF4 is the classical transcription factor partner of
β-catenin, the report showed that YAP did not activate
β-catenin on the TCF4 reporter. Nevertheless, in some
other context such as mouse intestine and cardiomyocytes,
activation of YAP due to inhibition of the Hippo pathway
correlates with activation of β-catenin/TCF4 target genes
[58,89]. Furthermore, YAP co-occupy gene promoters with
β-catenin [89]. Therefore, the functional transcription
factor partners of the YAP-β-catenin complex are not
completely understood and could be context-dependent.
Nevertheless, the above studies suggest a nuclear role of
YAP/TAZ in modulating gene expression regulation and
biological effects of the Wnt signaling pathway (Figure 1).
However, YAP/TAZ may also modulate the Wnt path-
way through cytoplasmic mechanisms (Figure 1). In cul-
tured cells, it was found that overexpression of YAP/
TAZ inhibits β-catenin/TCF4 reporter activity and
knockdown of YAP/TAZ activates it [90,91]. At the first
look this would be contradictory to the nuclear function
of YAP/TAZ in promoting beta-catenin activity. How-
ever, it was then demonstrated that cytoplasmic YAP
and TAZ are the main force in inhibiting β-catenin.
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the cytoplasm or cytoplasmic TAZ may sequester DVL2
impeding its activity to promote β-catenin accumulation
in response to Wnt stimulation [90,91]. So that nuclear
and cytoplasmic YAP/TAZ may have opposite roles in
regulating β-catenin activity. The Hippo pathway is the
best known mechanism for promoting cytoplasmic
localization of YAP/TAZ. Thus the Hippo pathway may
inhibit Wnt signaling through two distinct mechanisms,
by repressing YAP/TAZ/β-catenin activity in cell nuclei
and by promoting β-catenin cytoplasmic retention and
possibly degradation.
Wnt pathway plays a key role in intestinal stem cell self-
renewal and intestinal regeneration [85]. The function of
YAP/TAZ in intestinal regeneration was also examined.
Consistent with the role of YAP in promoting β-catenin
activity in the nucleus and the growth promoting activity
of itself, it was found that inactivation of YAP severely im-
pairs dextran sodium sulfate (DSS)-induced intestinal
regeneration, although YAP activity seems dispensable dur-
ing development and normal homeostasis [18]. Note-
worthy, the absence of phenotypes in YAP knockout
intestines could be due to compensation by TAZ. During
regeneration, YAP protein level was found to be elevated.
Similarly, inactivation of Mst1 and Mst2 in mouse intes-
tine also increases the protein level of YAP [58]. It was un-
clear whether the change of YAP protein level is related to
Wnt signaling. However, further another group demon-
strated that in irradiation-induced intestine regeneration
model, loss of YAP leads to overexpansion of intestinal
stem cells and development of microadenomas, which cor-
relates with hyperactive Wnt signaling [19]. This finding
would support an inhibitory role of YAP on Wnt signaling
during regeneration although the underlying reason for
differential YAP functions in the two intestine regeneration
models is unknown. More surprisingly, although it was
previously demonstrated that transgenic expression of anFigure 2 Phenotypes of intestinal crypt cells in animal models concer
The protein level and subcellular localization of YAP in crypt cells of each m
β-catenin in cell nucleus is also shown. However, for simplicity, the mechan
β-catenin does not suggest the change of total β-catenin protein level or sactive YAP-S127A mutant strongly expands intestinal pro-
genitors [39], tissue-specific expression of wild-type YAP
leads to a progressive degeneration phenotype associated
with loss of crypts and hypoactive Wnt signaling [19]. This
would indicate that YAP, even the transgenicly expressed
YAP is under inhibition by the Hippo pathway in intestinal
epithelium, so that the Hippo pathway hypo-responsive
S127A YAP mutant has different function from the wild-
type protein. Furthermore, other than simply inactive, the
extra abundant presumably cytoplasmic wild-type YAP
protein plays some roles other than the nuclear YAP pro-
tein. The activity is possible as proposed to be the inhib-
ition of β-catenin activity by restricting nuclear localization
of DVL. It is worth noting that the intestinal phenotypes
and altered Wnt signaling activity observed in wild-type
YAP transgenic model and in YAP knockout model under
irradiation-induced regeneration condition may be alterna-
tively explained by loss or gain of Paneth cells due to the
activity of YAP on cell differentiation [92]. Paneth cells
serve as an important part of the stem cell niche and a
major source of the Wnt ligand. Thus clarify the functions
of YAP/TAZ in intestinal stem cells and their niche would
be a crucial future direction. We summarized the complex
phenotypes of intestinal crypt cells in reported mouse
models concerning the cross-talk between the Hippo and
Wnt pathways (Figure 2). Similar to the situation in intes-
tinal regeneration, there are also contradictory reports on
the correlation between YAP and colon cancer. YAP was
reported to be both elevated in cancer and associated with
a better prognosis [19,21,58]. A better understanding of
the role of YAP in this disease would need a more quanti-
tative assay for YAP level and localization and more high
quality patient samples with disease progression data.
Conclusions
YAP and TAZ transcription coactivators play key roles in
organ size control, regeneration, and cancer development.ning the cross-talk between the Hippo and Wnt pathways.
ouse model are illustrated. The amount of transcriptionally active
isms are not reflected and the amount of transcriptionally active
ubcellular localization.
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way mediated phosphorylation and other mechanisms, the
upstream physiological signals controlling YAP/TAZ activ-
ity has been elusive for a long time. Nevertheless, recent
discoveries of YAP/TAZ as mediators of mechanical
stress, GPCR signaling, and Wnt signaling open up the
window to understand YAP/TAZ regulation under a com-
plex physiological context in vivo with both physical and
chemical properties. However, it is important to realize
that in all three cases, key molecular mechanisms are still
missing or are complicated by contradictory reports. For
example, it is unclear how F-actin cytoskeleton regulates
Lats1/2 kinase activity, which is important for YAP/TAZ
regulation by both mechanical stress and GPCR signaling.
Furthermore, identify of the possibly existing Lats1/2-in-
dependent mechanism of YAP/TAZ regulation by F-actin
remodeling is yet to be uncovered. Moreover, the nuclear
and cytoplasmic roles of YAP/TAZ in regulation of
β-catenin activity need to be clarified and the mechanisms
await further validation. In addition, the specificity and
possibly differential roles of YAP and TAZ in mediating
the above signals and in tissue regeneration and cancer
also require more precise assessments. It is also interesting
to understand how YAP/TAZ may serve to integrate dif-
ferent signals to mediate a proper response to the
dynamic in vivo environment. For example, both mechan-
ical stress and GPCR signaling input into regulation of
Rho activity and thus affects YAP/TAZ activity. Therefore,
it is interesting to know whether Rho serve as a check-
point for both the physiological environment and the
availability of chemical GPCR ligands to decide on cell
proliferation and differentiation. Despite the existence of
so many questions to be answered, the YAP/TAZ tran-
scription coactivators are undoubtedly important media-
tors of physiological signals in regulation of organ size
control, regeneration and tumorigenesis.
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